The effect of convalescent plasma therapy on mortality among patients with COVID-19: systematic review and meta-analysis

SA Klassen, JW Senefeld, PW Johnson, RE Carter… - Mayo Clinic …, 2021 - Elsevier
To determine the effect of COVID-19 convalescent plasma on mortality, we aggregated
patient outcome data from 10 randomized clinical trials, 20 matched control studies, 2 dose …

Use of convalescent plasma in COVID‐19 patients with immunosuppression

JW Senefeld, SA Klassen, SK Ford, KA Senese… - …, 2021 - Wiley Online Library
In the absence of effective countermeasures, human convalescent plasma has been widely
used to treat severe acute respiratory syndrome coronavirus 2, the causative agent of novel …

COVID-19 convalescent plasma for the treatment of immunocompromised patients: a systematic review and meta-analysis

JW Senefeld, M Franchini, C Mengoli… - JAMA Network …, 2023 - jamanetwork.com
Importance Patients who are immunocompromised have increased risk for morbidity and
mortality associated with coronavirus disease 2019 (COVID-19) because they less …

Treatment of chronic or relapsing COVID-19 in immunodeficiency

LAK Brown, E Moran, A Goodman, H Baxendale… - Journal of Allergy and …, 2022 - Elsevier
Background Patients with some types of immunodeficiency can experience chronic or
relapsing infection with severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) …

Treatment of COVID-19 with remdesivir in the absence of humoral immunity: a case report

MS Buckland, JB Galloway, CN Fhogartaigh… - Nature …, 2020 - nature.com
The response to the coronavirus disease 2019 (COVID-19) pandemic has been hampered
by lack of an effective severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) …

Outcome of SARS-CoV-2 infection in 121 patients with inborn errors of immunity: a cross-sectional study

ES Goudouris, F Pinto-Mariz, LO Mendonca… - Journal of clinical …, 2021 - Springer
Purpose There is still scarce data on SARS-CoV-2 infection in patients with Inborn Errors of
Immunity (IEI) and many unresolved questions. We aimed to describe the clinical outcome of …

COVID-19 in B cell-depleted patients after rituximab: a diagnostic and therapeutic challenge

A Furlan, G Forner, L Cipriani, E Vian, R Rigoli… - Frontiers in …, 2021 - frontiersin.org
B cell-targeting strategies such as rituximab are widely used in B cell hematologic
malignancies, rheumatologic and musculoskeletal diseases and a variety of autoimmune …

Impact of SARS-CoV-2 infection and COVID-19 on patients with inborn errors of immunity

SG Tangye, L Abel, S Al-Muhsen, A Aiuti… - Journal of Allergy and …, 2023 - Elsevier
Since the arrival of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in
December 2019, its characterization as a novel human pathogen, and the resulting …

Minor clinical impact of COVID-19 pandemic on patients with primary immunodeficiency in Israel

N Marcus, S Frizinsky, D Hagin, A Ovadia… - Frontiers in …, 2021 - frontiersin.org
In the last few months the world has witnessed a global pandemic due to severe acute
respiratory syndrome-coronavirus-2 (SARS-CoV-2) infection causing coronavirus disease …

Convalescent plasma therapy for COVID-19: a graphical mosaic of the worldwide evidence

SA Klassen, JW Senefeld, KA Senese… - Frontiers in …, 2021 - frontiersin.org
Convalescent plasma has been used worldwide to treat patients hospitalized with
coronavirus disease 2019 (COVID-19) and prevent disease progression. Despite global …